A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS
- Registry ID
- J2T-MC-KGBS
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2026-01-19
- Last update
- 2025-10-23
Conditions
- SEASONAL ALLERGIC RHINITIS
Related clinical trials
- "A STUDY TO EVALUATE THE EFFICACY OF DUPILUMAB AS AN ADJUNCT FOR SUBCUTANEOUS GRASS IMMUNOTHERAPY TO REDUCE PROVOKED ALLERGIC RHINITIS SYMPTOMS USING THE NASAL ALLERGEN CHALLENGE MODEL"
- A SINGLE-CENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PARALLEL-GROUP, COMPARATIVE ENVIRONMENTAL EXPOSURE CHAMBER (EEC) STUDY TO EVALUATE EFFICACY, SAFETY AND TOLERABILITY OF TWO FIXED DOSE COMBINATION (FDC) PRODUCTS OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE NASAL SPRAY AS COMPARED TO THE FDC OF AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE NASAL SPRAY, OLOPATADINE NASAL SPRAY, AND PLACEBO IN PATIENTS WITH SEASONAL ALLERGIC RHINITIS
- EFFICACY AND SAFETY OF INTRANASAL S0597 IN AN ENVIRONMENTAL EXPOSURE UNIT MODEL OF SEASONAL ALLERGIC RHINITIS: A PHASE 2, SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO, AND ACTIVE-CONTROLLED PARALLEL GROUP STUDY
View on source registry